Medicine profile
Dulaglutide
Once-weekly GLP-1 receptor agonist for type 2 diabetes.
- Generic name
- Dulaglutide
- Also known as
- Trulicity
- Sponsor and licensing
- Eli Lilly (originator)
- Mechanism
- GLP-1 receptor agonist
- Molecular type
- Peptide (Fc fusion) (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Trulicity
subcutaneous 路 once-weekly injection
- United States: Type 2 diabetes (glycaemic control) (18 Sep 2014)
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | 18 Sep 2014 路 TrulicityType 2 diabetes (glycaemic control) | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Dulaglutide
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Dulaglutide. Approved medicines only carry forecasts for new indications or jurisdictions when a filing anchor exists.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| AWARD-5Eli Lilly 路 subcutaneous, once weekly | 3 | 1,098 adults with type 2 diabetes inadequately controlled on metformin | 26 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Dulaglutide. The current official label in each jurisdiction is the authority on indications, populations and safety. Official records read for this profile: Drugs@FDA: BLA 125469 Trulicity (dulaglutide) approval history.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
No news articles yet for Dulaglutide.